In conclusion, the data presented here demonstrate that the anti-CCR7 mAb has a notable anti-tumor efficacy, causing a significant delay of the tumor growth rate and metastatic process in the subcutaneous model and also hindering lymphoma cells dissemination in the intravenous model. This evidence concerns the gene CCR7 and neoplasm.